Last reviewed · How we verify
Kolbet (IGURATIMOD)
Kolbet (generic name: IGURATIMOD) is a drug. It is currently FDA-approved for Rheumatoid arthritis.
Kolbet is a small molecule inhibitor of the macrophage migration inhibitory factor. It is a drug that belongs to the class of inhibitors.
At a glance
| Generic name | IGURATIMOD |
|---|---|
| Target | Macrophage migration inhibitory factor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Rheumatoid arthritis
Common side effects
Key clinical trials
- Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement (NA)
- Clinical Trial of Huoluo Pills Combined With Iguratimod Tablets in the Treatment of Rheumatoid Arthritis (NA)
- Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP (PHASE2)
- A Study of Iguratimod in Combination With Tofacitinib in RA Patients (PHASE4)
- A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX) (PHASE3)
- The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome (PHASE4)
- Efficacy Study of Iguratimod Combined With Tofacitab in Patients With RF Positive/Negative Rheumatoid Arthritis (PHASE4)
- Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHD (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Kolbet CI brief — competitive landscape report
- Kolbet updates RSS · CI watch RSS
Frequently asked questions about Kolbet
What is Kolbet?
Kolbet (IGURATIMOD) is a Small molecule drug, indicated for Rheumatoid arthritis.
What is Kolbet used for?
Kolbet is indicated for Rheumatoid arthritis.
What is the generic name of Kolbet?
IGURATIMOD is the generic (nonproprietary) name of Kolbet.
What development phase is Kolbet in?
Kolbet is FDA-approved (marketed).
What does Kolbet target?
Kolbet targets Macrophage migration inhibitory factor.
Related
- Target: All drugs targeting Macrophage migration inhibitory factor
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Rheumatoid arthritis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing